NASDAQ:DYN Dyne Therapeutics Q4 2025 Earnings Results & Report $14.83 -0.47 (-3.07%) As of 12:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Dyne Therapeutics missed analyst earnings expectations in its Q4 2025 results, released March 2, 2026. The company reported EPS of -$0.76 versus the -$0.74 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 2, 2026TimeBefore Market OpensConference Call7:00 AM ET Dyne Therapeutics EPS ResultsActual EPS-$0.76Consensus EPS -$0.74Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersDyne Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsDyne Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, October 29, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K)Annual report Dyne Therapeutics Q4 2025 Earnings FAQ Did Dyne Therapeutics beat earnings estimates for Q4 2025? Dyne Therapeutics (NASDAQ:DYN) reported earnings of -$0.76 per share for Q4 2025, missing the consensus estimate of -$0.74. The report was announced on Monday, March 2, 2026. When is Dyne Therapeutics' next earnings date? Dyne Therapeutics' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dyne Therapeutics on the company's earnings history page. Dyne Therapeutics Earnings HeadlinesDyne Therapeutics, Inc. (DYN) - What Are Investment Firms Saying About This Stock?October 11 at 2:29 AM | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Stock: Insider Brian Posner Purchases 2,500 SharesOctober 8, 2026 | americanbankingnews.comTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.October 14 at 1:00 AM | Monument Traders Alliance (Ad)Why Dyne Therapeutics (DYN) Is Back In The SpotlightOctober 7, 2026 | finance.yahoo.comFY2028 Earnings Forecast for DYN Issued By HC WainwrightOctober 4, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)October 1, 2026 | theglobeandmail.comSee More Dyne Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email. Email Address About Dyne TherapeuticsDyne Therapeutics (NASDAQ:DYN) is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues. Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping. The company has also pursued additional programs for rare muscle diseases, including Pompe disease. These candidates remain subject to clinical testing and regulatory review. Founded in 2018 and headquartered in Waltham, Massachusetts, Dyne conducts research and clinical-development activities in the United States and through international trial networks. The company has been led by Chief Executive Officer John Cox, who joined Dyne after serving in senior leadership roles in the biotechnology industry. Dyne’s common stock trades on the Nasdaq under the symbol DYN.View Dyne Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
